Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2022 Earnings Call Transcript

But the first step is, of course, getting there, which, which we’re really excited for at the second half of this year. And then, yes, sorry, I was just asking my colleagues on the second question around investment in early stage programs. Yes. So there, what we have said is right now, that is an outcome of the difference between the revenues, we bring in the expenses, we have to support those revenues. And then that goal of profitability, so this year, it’s a very judicial amount of investment. However, we are answering key questions, I think across each of those three programs. Our goal would be to continue to make progress there over the course of this year, and I think you’ll hear us towards the end of the year and sort of next year begins to give better line of sight in terms of what our vision is for those programs.

We still very much believe we have differentiated trans genes in Pompe and Fabry and are very excited about the opportunity to deliver those effectively in those therapies. And again, we also see the next generation chaperone is a really important part of our commitment to continue to develop medicines for Fabry disease. So more to come there but right now, again, it’s a very judicious but I think appropriate portion of our investment.

Zhiqiang Shu: Thank you very much.

Operator: Thank you. That was your last question. This concludes today’s conference call. Thank you and have a great day.

Bradley Campbell: Thank you, everybody. Appreciate the questions. Good luck. Good day.